Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, Ania, Amanat, Fatima, Firpo, Adolfo, Altman, Deena R., Bailey, Mark J., Mansour, Mayce, McMahon, Meagan, Meade, Philip +10 more·2020·Science
DOI 10.1126/science.abd7728

Cited by (1,007)

Items 501–600 of 1,007

  1. Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study
    Mary K. Foley, Samuel D. Searle, Ali Toloue Ostadgavahi, Ryan Booth, Alec Falkenham, Darryl Falzarano, Salvatore Rubino, Magen Ellen Francis, Mara McNeil, Christopher Richardson et al. · 2021 · EClinicalMedicine
  2. Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
    Padmanabha D. Shenoy, Sakir Ahmed, K. C. Shanoj, Veena Shenoy, Deepak Damodaran, Aparna R Menon, Bazil Alias, SanjoSaijan, Divya Devakumar, AS Sageer Babu · 2021 · Clinical Rheumatology
  3. A Brief Overview of COVID-19 Vaccines
    Dariush D Farhud, Shaghayegh Zokaei · 2021 · Iranian Journal of Public Health
  4. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity
    Jun Wu, Bo-Yun Liang, Yaohui Fang, Hua Wang, Xiaoli Yang, Shū Shěn, Liangkai Chen, Sumeng Li, Sihong Lu, Tiandan Xiang et al. · 2021 · Frontiers in Immunology
  5. Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh
    Mohd. Raeed Jamiruddin, Md. Ahsanul Haq, Mohib Ullah Khondoker, Tamanna Ali, Firoz Ahmed, Shahad Saif Khandker, Md. Irfan Jawad, Rubel Hossain, Sohel Ahmed, Sabita Rezwana Rahman et al. · 2021 · Expert Review of Vaccines
  6. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
    Jitka Smetanová, Zuzana Ozaniak Strizova, Anna Šedivá, Tomáš Milota, Rudolf Horváth · 2021 · The Lancet Rheumatology
  7. The serological diversity of serum IgG/IgA/IgM against SARS‐CoV‐2 nucleoprotein, spike, and receptor‐binding domain and neutralizing antibodies in patients with COVID‐19 in Japan
    Yudai Kaneko, Akira Sugiyama, Toshiya Tanaka, Kazushige Fukui, Akashi Taguchi, Kenji Tatsuno, Aya Nakayama, Kazumasa Koga, Yoshiro Kishi, Wang Daming et al. · 2022 · Health Science Reports
  8. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses
    Joseph Torresi, Melissa Anne Edeling, Terry M. Nolan, Dale Ian Godfrey · 2022 · Frontiers in Immunology
  9. New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
    Gemma E. Hartley, Emily S.J. Edwards, Robyn E. O’Hehir, Menno C. van Zelm · 2022 · Allergy
  10. State of the Art in Epitope Mapping and Opportunities in COVID-19
    Samira M. Hamed, Masarra M. Sakr, Ghadir S. El-Housseiny, Reham Wasfi, Khaled M. Aboshanab · 2023 · Future Science OA
  11. Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination
    Bennett Davenport, Thomas E. Morrison, Ross M. Kedl, Jared S. Klarquist · 2021 · The Journal of Immunology
  12. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
    Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen R. Wagstaffe et al. · 2020 · SSRN Electronic Journal
  13. Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
    Jesse J. Veenstra, Jie Wang, Kathleen McKinnon-Maksimowicz, Tingting Liu, Bobby Zuniga, Iltefat H. Hamzavi, Li Zhou, Qing-Sheng Mi · 2021 · Annals of the Rheumatic Diseases
  14. Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis
    Shuchi Anand, Maria E. Montez‐Rath, Jialin Han, Pablo García, LinaCel Cadden, Patti Hunsader, RUSSELL L. KERSCHMANN, Paul Beyer, Scott Dexter Boyd, Glenn Matthew Chertow et al. · 2021 · Annals of Internal Medicine
  15. Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test
    Mariângela Freitas da Silveira, Marília Arndt Mesenburg, Odir Antônio Dellagostin, Natasha Rodrigues de Oliveira, Mara Andrade Colares Maia, Francisco Denis Souza Santos, Andre Macedo Vale, Ana Maria Baptista Menezes, Gabriel D. Victora, Cesar Gomes Victora et al. · 2021 · The Brazilian Journal of Infectious Diseases
  16. CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
    Alessandra Noto, Victor Joo, Antonio Mancarella, Madeleine Suffiotti, Céline Pellaton, Craig W. Fenwick, Matthieu Perreau, Giuseppe Pantaleo · 2022 · Viruses
  17. Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
    Manish K. Dhawan, AbdulRahman A. Saied, Manish Kumar Sharma · 2023 · Health Sciences Review
  18. Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses
    Patrick W. G. Mallon, Willard Tinago, A. Léon, Kathleen McCann, Grace Kenny, Pádraig McGettrick, Sandra Green, Rosanna Inzitari, Aoife G. Cotter, Eoin R. Feeney et al. · 2021 · Open Forum Infectious Diseases
  19. Practical guidance for clinical laboratories for SARS-CoV-2 serology testing
    Carmen L. Charlton, Jamil N. Kanji, Vanessa Tran, Julianne V. Kus, Jonathan B. Gubbay, Carla Osiowy, Jason Lorne Robinson, Inna Sekirov, MICHAEL A. DREBOT, Todd F. Hatchette et al. · 2021 · Canada Communicable Disease Report
  20. Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
    Yalçın Pısıl, Zafer Yazıcı, Hisatoshi Shida, Tomoyuki Miura · 2021 · Pathogens
  21. Persistence of humoral response upon SARS‐CoV‐2 infection
    Andrea Knies, Dennis Ladage, Ralf J. Braun, Janine Kimpel, Miriam Schneider · 2021 · Reviews in Medical Virology
  22. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection
    Katherine A. Bond, Eloise Williams, Suellen R Nicholson, Seok Ming Lim, Douglas Forsyth Johnson, B. Cox, Mark Putland, Emma Gardiner, Emma Tippett, Maryza Graham et al. · 2021 · Pathology
  23. Immunology of SARS-CoV-2 infections and vaccines
    Dominik Schenten, Deepta Bhattacharya · 2021 · Advances in immunology
  24. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring
    Maria E. Moeller, Frederik Neess Engsig, Melanie Bade, Jeppe Fock, Pearlyn Pah, Anna Louise Soerensen, Didi Bang, Marco Donolato, Thomas Benfield · 2022 · Microbiology Spectrum
  25. Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients
    Christophe Capelle, Séverine Ciré, Olivia Domingues, Isabelle Ernens, Fanny Hedin, Aurélie Fischer, Chantal J. Snoeck, Wim Ammerlaan, Maria Konstantinou, Kamil Grzyb et al. · 2022 · Cell Reports Medicine
  26. Breakthrough SARS-CoV-2 infections after vaccination: a critical review
    Zainab Mohseni Afshar, M. Barary, R. Hosseinzadeh, Amirmasoud Alijanpour, Dariush Hosseinzadeh, S. Ebrahimpour, Kosar Nazary, Terence T. Sio, M. Sullman, Kristin V. Carson-Chahhoud et al. · 2022 · Human Vaccines & Immunotherapeutics
  27. Face masking and COVID-19: potential effects of variolation on transmission dynamics
    Zachary Levine, David J. D. Earn · 2022 · Journal of The Royal Society Interface
  28. SARS-CoV-2 Infection Is Associated with Uncontrolled HIV Viral Load in Non-Hospitalized HIV-Infected Patients from Gugulethu, South Africa
    Humaira Lambarey, Melissa J. Blumenthal, Abeen Chetram, Wendy Joyimbana, Lauren Jennings, Marius Belmondo Tincho, Wendy A. Burgers, Catherine Orrell, Georgia Schäfer · 2022 · Viruses
  29. SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
    Marjut Sarjomaa, Lien My Diep, Chi Zhang, Yngvar Tveten, Harald Reiso, Carina Thilesen, Svein Arne Nordbø, Kristine Karlsrud Berg, Ingeborg Sundsvalen Aaberge, Neil E. Pearce et al. · 2022 · PLoS ONE
  30. Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 years
    Mariana Pavel Tanasa, Daniela Constantinescu, Corina Maria Cianga, Ecaterina Anisie, Ana Irina Mereuţă, Cristina Tuchiluş, Petru Cianga · 2022 · Frontiers in Immunology
  31. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
    Li, Cesheng, Yu, Ding, Wu, Xiao, Liang, Hong, Zhou, Zhijun, Xie, Yong, Li, Taojing, Wu, Junzheng, Lu, Fengping, Feng, Lu et al. · 2021
  32. 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
    Florian Deisenhammer, Wegene Borena, Angelika Bauer, Janine Kimpel, Dagmar Rudzki, Kathrin Schanda, Jonas Egeter, Katharina Hüfner, Barbara Sperner‐Unterweger, Markus Reindl · 2020 · Wiener klinische Wochenschrift
  33. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
    Tamiris Azamor, Ingrid Siciliano Horbach, Danielle Brito e Cunha, Juliana Gil Melgaço, Andréa Marques Vieira da Silva, Luciana Neves Tubarão, Adriana de Souza Azevedo, Renata Tourinho Santos, Nathalia dos Santos Alves, Thiago Lazari Machado et al. · 2022 · Viruses
  34. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months
    Cary Suzanne Lea, Kristina L. Simeonsson, Aaron M. Kipp, Charleen McNeill, Lisa Wilcox, William D Irish, Hannah Morris, Omar Diaz, John T. Fallon, Rachel L. Roper · 2022 · Vaccines
  35. An update on SARS-CoV-2 immunization and future directions
    Rashmi Rana, Ravi Kant, Tanya Kumra, Sneha V. Gupta, Devinder Singh Rana, Nirmal Kumar Ganguly · 2023 · Frontiers in Pharmacology
  36. Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination
    Nadine Benhamouda, Anissa Besbes, Rebecca Bauer, Nesrine Mabrouk, Gauthier Gadouas, Corinne Desaint, Lucie Chevrier, Maeva Lefebvre, Anne Radenne, Marie Roelens et al. · 2024 · iScience
  37. Anti‐spike S1 receptor‐binding domain antibodies against SARS‐CoV‐2 persist several months after infection regardless of disease severity
    Davide Fiore Bavaro, Paola Laghetti, Eugenio Milano, Gaetano Brindicci, Anna Rita Volpe, Antonella Lagioia, Annalisa Saracino, Laura Monno · 2021 · Journal of Medical Virology
  38. Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK
    Madhumita Shrotri, Ross Harris, Alison J. Rodger, Tim Planche, Frances Sanderson, Tabitha W. Mahungu, Alastair C. McGregor, Paul Trafford Heath, The LondonCOVID Group, Colin Stewart Brown et al. · 2021 · Emerging infectious diseases
  39. A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh
    Pritimoy Das, Syed Moinuddin Satter, Allen Guy Ross, Zarin Abdullah, Arifa Nazneen, Rebeca Sultana, Nadia Ali Rimi, Kamal Ibne Amin Chowdhury, Muhammad Rashedul Alam, Shahana Parveen et al. · 2021 · Tropical Medicine and Infectious Disease
  40. SARS‐CoV‐2 antibodies started to decline just four months after COVID‐19 infection in a paediatric population
    Adin Breuer, Allon Raphael, Hagay Stern, Ma'aran Odeh, Judith Fiszlinski, Nurit Algur, Sophie Magen, Orli Megged, Yechiel Schlesinger, Yuval Barak‐Corren et al. · 2021 · Acta Paediatrica
  41. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques
    T. Nomura, Hiroyuki Yamamoto, M. Nishizawa, T. Hau, S. Harada, Hiroshi Ishii, Sayuri Seki, Midori Nakamura-Hoshi, Midori Okazaki, Sachie Daigen et al. · 2021 · bioRxiv
  42. Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
    Juan P. Wisnivesky, Kimberly Stone, Emilia Bagiella, Molly Doernberg, Damodara Rao Mendu, Jenny J. Lin, Minal Kale · 2021 · Journal of General Internal Medicine
  43. Advances in understanding the formation and fate of B-cell memory in response to immunization or infection
    Liam C. Kealy, Kim L. Good‐Jacobson · 2021 · Oxford Open Immunology
  44. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection
    Harmony L. Tyner, Jefferey L. Burgess, Lauren Grant, Manjusha Gaglani, Jennifer L. Kuntz, Allison L. Naleway, Natalie J. Thornburg, Alberto Juan Caban-Martinez, Sarang K. Yoon, Meghan K. Herring et al. · 2021 · Clinical Infectious Diseases
  45. Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters
    Cassandra J. Field, Talia A. Heinly, Dolly Patel, Derek G. Sim, Erin Luley, Sneh Lata Gupta, Thomas H. Vanderford, Jens Wrammert, Troy C. Sutton · 2022 · Emerging Microbes & Infections
  46. Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples
    Laura Lahdentausta, Anne S. Kivimäki, Lotta‐Maria Oksanen, Marika Tallgren, Sampo A. Oksanen, Enni Sanmark, Aino Salminen, Ahmed Geneid, Mikko Sairanen, Susanna Paju et al. · 2022 · Medical Microbiology and Immunology
  47. COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study
    Amelia Sancilio, Joshua M. Schrock, Alexis R. Demonbreun, Richard T. D’Aquila, Brian S. Mustanski, Lauren A. Vaught, Nina L. Reiser, Matt P. Velez, Ryan R. Hsieh, Daniel T. Ryan et al. · 2022 · Scientific Reports
  48. COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
    Aliya Jaber, Meera H. Patel, Andrew Sylvester, Mary Yarussi, Jennifer Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay · 2023 · Neurology and Therapy
  49. Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data
    Shannon L. Reynolds, Harvey W. Kaufman, William A. Meyer, Chris Bush, Oren J. Cohen, Kathy A. Cronin, Carly A. Kabelac, Sandy Leonard, Steve Anderson, Valentina I. Petkov et al. · 2023 · PLoS ONE
  50. Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population
    Adam Abdullahi, James Opoku Frimpong, Mark T. K. Cheng, Sani Hussein Aliyu, Colette J Smith, Alash’le Abimiku, Richard Odame Phillips, Michael Owusu, Ravindra K. Gupta · 2023 · American Journal of Tropical Medicine and Hygiene
  51. Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors
    Kyle Annen, Thomas E. Morrison, Melkon G. DomBourian, Mary K. McCarthy, Leah Huey, Patricia A. Merkel, Gillian Andersen, Eileen Schwartz, Vijaya Knight · 2021 · Transfusion
  52. Saliva-Based ELISAs for Effective SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals
    Joseph G. Casian, Aaron N. Angel, Ronell Lopez, Cedie Bagos, Melanie A. MacMullan, Mindy L. Bui, Prithivi Chellamathu, Sudipta Sekhar Das, Fred Turner, Vladimir I. Slepnev et al. · 2021 · Frontiers in Immunology
  53. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV
    Myrthe L. Verburgh, Anders C. Boyd, Ferdinand W.N.M. Wit, Maarten F. Schim van der Loeff, Marc van der Valk, Margreet E. Bakker, Neeltje A. Kootstra, Lia van der Hoek, Peter Reiss · 2021 · The Journal of Infectious Diseases
  54. Relationship between Lung and Brain Injury in COVID-19 Patients: A Hyperpolarized 129Xe-MRI-based 8-Month Follow-Up
    Shizhen Chen, Yina Lan, Haidong Li, Liming Xia, Chaohui Ye, Xin Lou, Xin Hua Zhou · 2022 · Biomedicines
  55. Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut
    Pavlos K. Papasavas, Sope Omowale Olugbile, Ulysses Wu, Kenneth J. Robinson, A.L. Roberts, David M. O’Sullivan, T. McLaughlin, Jeff Mather, A.C. Steinberg, R. Orlando et al. · 2021 · Journal of Hospital Infection
  56. Testing for antibodies to SARS-CoV-2
    Dipender Gill, Mark Ponsford · 2020 · BMJ
  57. The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
    Otto O. Yang · 2025 · The Journal of Immunology
  58. Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States
    Marie E. Killerby, Mohammed Ata Ur Rasheed, Azaibi Tamin, Jennifer L. Harcourt, Glen R. Abedi, Xiaoyan Lu, Stephanie A Kujawski, Melisa M. Shah, Hannah L. Kirking, Jeremy A.W. Gold et al. · 2021 · The Journal of Infectious Diseases
  59. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
    Sabrina Racine‐Brzostek, Mohsen Karbaschi, Christian Gaebler, Per Johan Klasse, Jim K. Yee, Marina F. Caskey, He S. Yang, Ying Hao, Ashley C. Sukhu, Sophie Rand et al. · 2021 · Clinical Chemistry
  60. Maintenance of neutralizing antibodies over ten months in convalescent SARS‐CoV‐2 afflicted patients
    Sissy Therese Sonnleitner, Martina Prelog, Bianca Jansen, Chantal Rodgarkia‐Dara, Sarah Gietl, Carmen Maria Schönegger, Stephan Koblmüller, Christian Sturmbauer, Wilfried Posch, Giovanni Almanzar et al. · 2021 · Transboundary and Emerging Diseases
  61. Disparities in the Evolution of the COVID-19 Pandemic between Spanish Provinces
    Héctor López-Mendoza, Antonio Montañés, Francisco J. Moliner-Lahoz · 2021 · International Journal of Environmental Research and Public Health
  62. Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression
    Bastian Fischer, Christopher Lindenkamp, Christoph Lichtenberg, Ingvild Birschmann, Cornelius Knabbe, Doris Hendig · 2021 · Life
  63. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Mina Psichοgiou, Andreas Karabinis, Garyphallia Poulakou, Anastasia Antoniadou, Αnastasia Kotanidou, Dimitrios Degiannis, Ioanna D. Pavlopoulou, Antigoni S. Chaidaroglou, Sotirios Roussos, Elpida Mastrogianni et al. · 2021 · Vaccines
  64. Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age
    Margarethe Konik, Monika Lindemann, Markus Zettler, Lara Meller, Sebastian Dolff, Vera Rebmann, Peter Alexander Horn, Ulf Dittmer, Adalbert Krawczyk, Leonie Schipper et al. · 2021 · Journal of Clinical Medicine
  65. Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic—Experience and Outlines
    Monica Teodora Neagu, Carolina Constantin, Mihaela Surcel · 2021 · International Journal of Environmental Research and Public Health
  66. An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants
    Argiris Asderakis, Usman Khalid, Georgios Koimtzis, Mark J. Ponsford, Laszlo Szabo, Christopher Chalklin, Kathryn Bramhall, Leanne Grant, Stuart J. Moat, Ian Robert Humphreys et al. · 2022 · Transplantation
  67. Comparison of the humoral and cellular immunity in COVID-19 convalescents
    А. П. Топтыгина, Elena L. Semikina, Закиров Рустам Шакирович, Zulfiia E. Afridonova · 2022 · Russian Journal of Infection and Immunity
  68. Antibody response to BNT162b2 mRNA vaccine in gingival crevicular fluid
    Pingping Han, Corey Stephen Moran, Srinivas Sulugodu Ramachandra, Laurence James Walsh, Sašo Ivanovski · 2022 · Journal of Periodontology
  69. SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults
    Malama Chisanga, Matthew Stuible, Christian Gervais, Denis L’Abbé, Brian Cass, Louis Bisson, Alex Pelletier, Simon Lord‐Dufour, Yves Durocher, Denis Boudreau et al. · 2022 · Sensors & Diagnostics
  70. Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers
    Aya Sugiyama, Akemi Kurisu, Shintaro Nagashima, Kiyomi Hando, Khilola Saipova, Sayyora Akhmedova, Kanon Abe, Hirohito Imada, Md Razeen Ashraf Hussain, Serge Ouoba et al. · 2022 · Scientific Reports
  71. Torquetenovirus viral load is associated with anti‐spike antibody response in SARS‐CoV‐2 mRNA BNT162b2 vaccinated kidney transplant patients
    Sara Querido, Teresa Adragão, Iola Pinto, Carolina Ormonde, Ana Luísa Papoila, Maria Ana Pessanha, Perpétua Gómes, Sílvia Ferreira, João M. Figueira, Conceição Cardoso et al. · 2022 · Clinical Transplantation
  72. Combined Antibodies Evusheld against the SARS-CoV-2 Omicron Variants BA.1.1 and BA.5: Immune Escape Mechanism from Molecular Simulation
    Jianwen Zhang, Yalong Cong, Lili Duan, John Z. H. Zhang · 2023 · Journal of Chemical Information and Modeling
  73. Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus
    Dan Yang, Xinglin Wang, Xu Yang, Shanshan Qi, Feiyu Zhao, Donghua Guo, Chunqiu Li, Qinghe Zhu, Xiaoxu Xing, Yang Cao et al. · 2024 · Virology
  74. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study
    Isa Murrell, Dónall Forde, Wioleta Milena Zelek, Linda Tyson, Lisa Chichester, Nicki Palmer, Rachel Jones, B. Paul Morgan, Catherine Moore · 2021 · PLoS ONE
  75. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy
    Immacolata Polvere, Alfredina Parrella, Giovanna Casamassa, Silvia D’Andrea, Annamaria Tizzano, Gaetano Cardinale, Serena Voccola, Piercarmine Porcaro, Romania Stilo, Pasquale Vito et al. · 2021 · Diagnostics
  76. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation
    Natalia Martínez-Acuña, Diana Minerva Avalos-Nolazco, Diana Raquel Rodríguez-Rodríguez, Cynthia Martinez-Liu, Rogelio Cázares-Tamez, Amador Flores-Aréchiga, Fernando Pérez‐Chávez, Sergio Ayala de la Cruz, Eduardo Cienfuegos‐Pecina, Erik Alejandro Díaz‐Chuc et al. · 2021 · Viruses
  77. Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
    Juan Manuel Carreño, Damodara Rao Mendu, Viviana R. Simon, Masood A Shariff, Gagandeep Singh, Vidya P. Menon, Florian Krammer · 2021 · iScience
  78. Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology
    Aaruni Khanolkar · 2021 · Cells
  79. COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions
    Ryan C. Ungaro, Michael D. Kappelman, David T. Rubin, Jean‐Frédéric Colombel · 2020 · Gastroenterology
  80. SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
    R. Duerr, Keaton M. Crosse, Ana M. Valero-Jimenez, Meike Dittmann · 2021 · Microorganisms
  81. A look-back at convalescent plasma to treat COVID-19
    Olivier Garraud, Karine Lacombe, Pierre Tiberghien · 2021 · Transfusion and Apheresis Science
  82. Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region
    Robert Daniel Heinrich Markewitz, Antje Torge, Klaus‐Peter Wandinger, Daniela Pauli, André Franke, Luís Bujanda, José María Marimón, Jesús M. Bañales, María A. Gutiérrez-Stampa, Beatriz Nafría Jiménez et al. · 2021 · Scientific Reports
  83. COVID-19 serological survey using micro blood sampling
    Melissa M. Matthews, Tae Gyun Kim, Satoshi Shibata, Noriko Shibata, Christian H. Butcher, Jaekyung Hyun, Keon Young Kim, Theodore Robb, Siang Sheng Jheng, Masashi Narita et al. · 2021 · Scientific Reports
  84. Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies
    Nathan Cook, Lingqing Xu, Shaymaa E. Hegazy, Bradley J. Wheeler, Adam Anderson, Nancy Critelli, Mary Yost, Anita K. McElroy, Michael R. Shurin, Sarah Wheeler · 2021 · Clinical Biochemistry
  85. Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients
    Bernadette Crescenzo-Chaigne, Sylvie Behillil, Vincent Enouf, Nicolas Escriou, Stéphane Pêtres, Marie Noëlle Ungeheuer, Jade Ghosn, Sarah Tubiana, Lila Bouadma, Sylvie van der Werf et al. · 2021 · Journal of Clinical Virology Plus
  86. Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China
    Shuiping Dai, Bennan Zhao, Dafeng Liu, Yongzhao Zhou, Yaling Liu, Lijuan Lan, Yalun Li, Wenxin Luo, Yilan Zeng, Weimin Li · 2021 · International Journal of General Medicine
  87. Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells in Whole Blood
    Andreas Törnell, Hanna Grauers Wiktorin, Johan Ringlander, Mohammad Arabpour, Malin Nilsson, Staffan Nilsson, Roberta Kiffin, Magnus Lindh, Martin Lagging, Kristoffer Hellstrand et al. · 2022 · The Journal of Infectious Diseases
  88. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
  89. Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
    Swatantra Kumar, Shailendra Kumar Saxena, Vimal K. Maurya, Anil Kumar Tripathi · 2022 · Frontiers in Immunology
  90. How to Motivate SARS-CoV-2 Convalescents to Receive a Booster Vaccination? Influence on Vaccination Willingness
    Elias Kowalski, Andreas Stengel, Axel Schneider, Miriam Goebel‐Stengel, Stephan Zipfel, Johanna Graf · 2022 · Vaccines
  91. Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination
    Doris Urlaub, Natalie Wolfsdorff, Jan‐Erik Hoffmann, Stefanie Dorok, Markus Hoffmann, Moritz Anft, Naomi Pieris, Patrick S. Günther, Bernhard Schaaf, Uwe Cassens et al. · 2022 · European Journal of Immunology
  92. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity
    Yoonjung Kim, Joon‐Yong Bae, Ki Tae Kwon, Hyun‐Ha Chang, Won Kee Lee, Heedo Park, Jeonghun Kim, Isaac Choi, Man‐Seong Park, Shin‐Woo Kim · 2022 · Scientific Reports
  93. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
    John Kubale, Charles Gleason, Juan Manuel Carreño, Komal Srivastava, Gagandeep Singh, PARIS Study Team, Aubree Gordon, Florian Krammer, Viviana R. Simon, Hala Alshammary et al. · 2022 · mBio
  94. Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients
    Sónia André, Marne Azarias-da-Silva, Morgane Picard, Aurélie Alleaume‐Butaux, Lucy Kundura, Renaud Cezar, Calaiselvy Soudaramourty, André Santa Cruz, Ana Mendes‐Frias, Alexandre Carvalho et al. · 2022 · Cell Death and Disease
  95. COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
    Sharon Lynn Walmsley, Leah Szadkowski, Bradly G. Wouters, Rosemarie Clarke, Karen Colwill, Paula A. Rochon, Michael Brudno, Rizanni Ravindran, Janet Raboud, Allison McGeer et al. · 2023 · iScience
  96. Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
    Gagandeep Singh, Anass Abbad, Johnstone Tcheou, Damodara Rao Mendu, Adolfo Firpo‐Betancourt, Charles Gleason, Komal Srivastava, Carlos Cordon-Cardo, Viviana R. Simon, Florian Krammer et al. · 2023 · The Journal of Infectious Diseases
  97. Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers
    Amit Bansal, Mai-Chi Trieu, Kristin Greve-Isdahl Mohn, Anders Madsen, Jan Stefan Olofsson, Helene Heitmann Sandnes, Marianne Sævik, Hanne Søyland, Lena Hansen, Therese Bredholt Onyango et al. · 2023 · Frontiers in Public Health
  98. Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK
    Naheed Choudhry, Kate Drysdale, Carla Usai, Dean Leighton, Vinay Jamnadas Sonagara, Ruaridh Buchanan, Manreet Nijjar, Sherine Thomas, Mark J Hopkins, Teresa Cutiño‐Moguel et al. · 2021 · Frontiers in Medicine
  99. Potent and Persistent Antibody Response in COVID-19 Recovered Patients
    Xiaodong Tian, Ling Liu, Wen-Guo Jiang, He Zhang, Wenjun Liu, Jing Li · 2021 · Frontiers in Immunology
  100. Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity
    Andreas Emanuel Kremer, Anita N. Kremer, Carsten Willam, Simon Völkl, Johan Verhagen, Susanne Achenbach, Edith D. van der Meijden, Vanessa Lang, Michael Aigner, Clara Maier et al. · 2021 · European Journal of Immunology